Advertisement
U.S. markets close in 1 hour 57 minutes

Aldeyra Therapeutics, Inc. (ALDX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.5441+0.1941 (+5.79%)
As of 02:00PM EST. Market open.

Aldeyra Therapeutics, Inc.

131 Hartwell Avenue
Suite 320
Lexington, MA 02421
United States
781 761 4904
https://www.aldeyra.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Todd C. Brady M.D., Ph.D.CEO, President & Director909.97kN/A1972
Mr. Bruce Greenberg CPA, M.B.A.Senior VP of Finance, Interim CFO & Treasurer396.54kN/A1968
Dr. Stephen G. Machatha Ph.D.Chief Development Officer579.57kN/A1977
Mr. Kelly MizerVice President of Commercial Strategy & OperationsN/AN/AN/A
David BurkeHead of Investor RelationsN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In addition, it develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.

Corporate Governance

Aldeyra Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2024 is 8. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.